20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor (pages 1277–1287)
Bo Cao, Xichun Liu, Jing Li, Shuang Liu, Yanfeng Qi, Zhenggang Xiong, Allen Zhang, Thomas Wiese, Xueqi Fu, Jingkai Gu, Paul S. Rennie, Oliver Sartor, Benjamin R. Lee, Clement Ip, Lijuan Zhao, Haitao Zhang and Yan Dong
Version of Record online: 20 AUG 2012 | DOI: 10.1002/ijc.27754
This is the first report on 20(S)-protopanaxadiol-aglycone as an effective agent to downregulate the expression and activity of the full-length androgen receptor and its constitutively-active splice variants in prostate cancer. It is also the first to show the in vivo efficacy of 20(S)-protopanaxadiol-aglycone against androgen-receptor-expressing prostate tumors. Considering the critical roles of androgen receptor and its splice variants in disease progression, our findings suggest that 20(S)-protopanaxadiol-aglycone is a promising agent for prostate cancer intervention.